Clinical trial
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease…
NCT00172068 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00172068 |
|---|---|
| Title | Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow |
| Official title | Efficacy and Tolerability of Intravenous Zometa® (Zoledronic Acid) 4 mg in Primary Breast Cancer Patients With Disseminated Tumor Cells in Bone Marrow. A Prospective, Randomized, Parallel Group, Open-label, Clinical Pilot Study. |
| Acronym | MRD-1 |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Breast Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid + Calcium/Vitamin D |
| Enrollment | 96 |
| Start date | Jan 1, 2002 |
| Primary completion | Nov 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 23, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: